Eliem Therapeutics Inc (ELYM)
7.10
+2.08
(+41.43%)
USD |
NASDAQ |
Apr 30, 16:00
7.08
-0.02
(-0.28%)
After-Hours: 07:15
Eliem Therapeutics Cash from Investing (Quarterly): 36.75M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 36.75M |
| September 30, 2023 | 28.04M |
| June 30, 2023 | -1.601M |
| March 31, 2023 | 5.797M |
| December 31, 2022 | 14.28M |
| September 30, 2022 | 8.509M |
| June 30, 2022 | 15.69M |
| Date | Value |
|---|---|
| March 31, 2022 | -4.035M |
| December 31, 2021 | -8.051M |
| September 30, 2021 | -106.92M |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 8.078M |
| September 30, 2020 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-106.92M
Minimum
Sep 2021
36.75M
Maximum
Dec 2023
-0.2479M
Average
2.898M
Median
Cash from Investing (Quarterly) Benchmarks
| Alpine Immune Sciences Inc | -112.70M |
| Candel Therapeutics Inc | -0.027M |
| Lipocine Inc | 2.727M |
| GlycoMimetics Inc | -0.0008M |
| Lyell Immunopharma Inc | -100.69M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.947M |
| Cash from Financing (Quarterly) | 0.288M |
| Free Cash Flow | -20.60M |
| Free Cash Flow Per Share (Quarterly) | -0.0344 |
| Free Cash Flow Yield | -10.75% |